SenzaGen AB Stock Nasdaq Stockholm
Equities
SE0010219626
Biotechnology & Medical Research
Sales 2024 * | 67.55M 6.2M 8.49M | Sales 2025 * | 91.65M 8.41M 11.52M | Capitalization | 169M 15.54M 21.29M |
---|---|---|---|---|---|
Net income 2024 * | -15M -1.38M -1.89M | Net income 2025 * | -4M -367K -503K | EV / Sales 2024 * | 2.39 x |
Net cash position 2024 * | 8M 734K 1.01M | Net cash position 2025 * | 9M 826K 1.13M | EV / Sales 2025 * | 1.75 x |
P/E ratio 2024 * |
-11.3
x | P/E ratio 2025 * |
-41.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61.56% |
Latest transcript on SenzaGen AB
Managers | Title | Age | Since |
---|---|---|---|
Peter Nählstedt
CEO | Chief Executive Officer | 50 | 17-12-31 |
Marianne Olsson
DFI | Director of Finance/CFO | 63 | 16-10-31 |
Henrik Johansson
CTO | Chief Tech/Sci/R&D Officer | 42 | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 76 | 10-08-17 | |
Director/Board Member | 59 | 14-10-14 | |
Paula Zeilon
BRD | Director/Board Member | 62 | 19-12-31 |
1st Jan change | Capi. | |
---|---|---|
-18.49% | 11.03B | |
+53.63% | 3.5B | |
-32.53% | 2.23B | |
-14.31% | 2.16B | |
-27.04% | 1.54B | |
+31.37% | 1.12B | |
-3.28% | 737M | |
-22.54% | 477M | |
-41.94% | 411M |